Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
1.42
-0.15 (-9.55%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.41 - 1.57
52 week 1.41 - 3.75
Open 1.57
Vol / Avg. 404,500.00/356,942.00
Mkt cap 164.90M
P/E     -
Div/yield     -
EPS -0.47
Shares 128.39M
Beta 1.77
Inst. own 57%
Feb 22, 2016
Q4 2015 Curis Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Feb 8, 2016
Curis Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference - 5:30PM EST - Add to calendar
Dec 9, 2015
Curis Inc at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -271.06% -190.27%
Operating margin -236.86% -161.14%
EBITD margin - -159.57%
Return on average assets -20.43% -26.16%
Return on average equity -28.40% -49.97%
Employees 35 -
CDP Score - -

Address

4 Maguire Rd
LEXINGTON, MA 02421-3112
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Curis, Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis' product pipeline also includes CUDC-427, an orally available, small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma, and human epidermal growth factor receptor 2 (HER 2-), estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Company's PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Daniel R. Passeri J.D. Vice Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Michael P. Gray Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jaye Viner M.D. Chief Medical Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Kenneth J. Pienta M.D. Director
Age: 55
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 73
Bio & Compensation  - Reuters
Kenneth I. Kaitin Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Martell M.D., Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters
Marc Rubin M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters